Prescribing information

 

Prescribing information

       

 

Speakers: 
Prof Paul Brogan 
Prof. Helen Lachmann 
Prof. Siniša Savić

This educational video can be viewed in its entirety (above), or as three separate topics (below), each presented by a different expert in the field of autoinflammatory diseases (AID):

  1. Autoinflammatory diseases: an overview of periodic fever syndromes (PFS) and Still’s Disease, and the unmet needs associated with their diagnosis and management.
  2. Interleukin-1ß mechanism of action and periodic fever syndromes (PFS) data: the role of interleukin-1β (IL-1β) in AID, an introduction to ILARIS® (canakinumab) and its MOA in AID, and a summary of the efficacy and safety profile of ILARIS in PFS.
  3. Autoinflammatory diseases diagnosis and monitoring for periodic fever syndromes (PFS): current classification of AID and recommendations for monitoring patients.
 

Autoinflammatory diseases

Watch Prof. Paul Brogan give an overview of the PFS, CAPS, TRAPS, HIDS/MKD and FMF, and Still’s disease, including their clinical features. He also explores the unmet needs and key treatment goals for these AIDs.  

 

Interleukin-1ß mechanism of action and periodic fever syndromes (PFS) data

Watch Prof. Siniša Savić explain the role of interleukin-1β in AID, before introducing a selective IL-1β inhibitor, ILARIS. Prof. Savic specifically looks at the position of ILARIS as a treatment option for patients with PFS by evaluating its efficacy, safety profile and quality of life data.

 
 

Autoinflammatory diseases diagnosis and monitoring for period fever syndromes (PFS)

Watch Prof. Helen Lachmann discuss the current classification of FMF, CAPS, TRAPS and HIDS/MKD. Prof Lachmann also evaluates the recommendations for monitoring patients during treatment and the course of their disease, including the use of the Autoinflammatory Diseases Activity index as descibed in ter Haar et al, 2015.1

 

Indications
Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:2

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • TRAPS
  • HIDS/MKD
  • FMF
    • ILARIS should be given in combination with colchicine, if appropriate.

Still's disease
ILARIS is indicated for the treatment of active Still's disease including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. ILARIS can be given as monotherapy or in combination with methotrexate.2

AID, autoinflammatory disease; CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HIDS/MKD, hyperimmunoglobulin D syndrome mevalonate kinase deficiency; PFS, periodic fever syndromes; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

Reference

  1. ter Haar NM, et al. Ann Rheum Dis 2015;74(9):1636–1644.

  2. ILARIS® (canakinumab) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | May 2022 | 200192
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com